MannKind(US:MNKD)2026-02-26 13:06Financial Position - As of December 31, 2025, the company had cash, cash equivalents, and investments totaling $176.4 million, with an accumulated deficit of $3.2 billion and a total stockholders' deficit of $51.0 million[355]. - Total material cash requirements as of December 31, 2025, amounted to $788.7 million, including financing liabilities and senior convertible notes[408]. - As of December 31, 2025, the company had cash, cash equivalents, and investments totaling $176.4 million, with outstanding borrowings of $361.3 million[422]. - The company expects to incur significant cash requirements for employee compensation, marketing expenses, and clinical trial costs[414]. - The company has a remaining obligation of $90.0 million under the Milestone Rights Agreement, with $45.0 million payable as of December 31, 2025[413]. - The company has a senior convertible note with a principal amount of $36.3 million, bearing interest at 2.50%[410]. - The company has a remaining lease obligation of $11.9 million under an operating lease in Bedford, Massachusetts, with monthly payments subject to annual increases[410]. Revenue and Income - The company reported a net income of $5.9 million for the year ended December 31, 2025, compared to a net income of $27.6 million and a net loss of $11.9 million for the years ended December 31, 2024 and 2023, respectively[355]. - Total revenues for the year ended December 31, 2025, were $348.97 million, an increase of $63.46 million, or 22%, compared to $285.50 million in 2024[377]. - Gross revenue from commercial product sales increased by $31.96 million, or 23%, to $168.09 million for the year ended December 31, 2025, compared to $136.13 million in 2024[377]. - Net revenue from collaborations and services increased by $5.9 million, or 6%, for the year ended December 31, 2025, primarily due to increased manufacturing volume for products sold to UT[380]. - Royalty revenue increased by $25.78 million, or 25%, for the year ended December 31, 2025, driven by UT's increase in net revenue from sales of Tyvaso DPI[380]. - Commercial product gross profit increased by $18.46 million, or 28%, to $83.36 million for the year ended December 31, 2025, compared to $64.90 million in 2024[384]. - Non-GAAP adjusted net income for the year ended December 31, 2025, was $59.5 million, with a basic EPS of $0.19, compared to $67.7 million and $0.25 in 2024[403]. Expenses - Total expenses increased by $97.25 million, or 46%, to $310.17 million for the year ended December 31, 2025, compared to $212.92 million in 2024[385]. - Research and development expenses increased by $20.46 million, or 45%, for the year ended December 31, 2025, primarily due to the ICoN-1 clinical study and clinical production scale-up for MNKD-201[386]. - Selling, general and administrative expenses increased by $49.81 million, or 53%, for the year ended December 31, 2025, reflecting costs associated with the promotion of Furoscix and transaction-related costs from the acquisition of scPharma[387]. - Interest income, net, decreased by $4.56 million, or 36%, to $8.05 million for the year ended December 31, 2025, primarily due to lower average balances on the securities portfolio[391]. - Interest expense increased by $1.8 million for the year ended December 31, 2025, primarily due to new term loans totaling $325.0 million drawn in August and October 2025[392]. - Interest expense on liability for sale of future royalties was $14.4 million for the year ended December 31, 2025, down from $16.2 million in 2024[393]. - Impairment of available-for-sale investment was $6.4 million for the year ended December 31, 2025, compared to $1.6 million in 2024[395]. - Gain on bargain purchase of $5.3 million was recorded for the year ended December 31, 2024, from the Pulmatrix Transaction[397]. Cash Flow - The company generated $18.3 million in cash from operating activities for the year ended December 31, 2025, with a net income of $5.9 million and non-cash adjustments totaling $58.3 million[416]. - Cash used in investing activities amounted to $304.8 million for the year ended December 31, 2025, primarily due to the acquisition of scPharma for $357.7 million[418]. - Cash provided by financing activities was $315.1 million for the year ended December 31, 2025, mainly from a term loan of $325.0 million under the Blackstone Credit Facility[420]. Business Development - The company anticipates two potential milestones for its cardiometabolic business in 2026, with the FDA reviewing a sBLA for Afrezza and a sNDA for Furoscix, both with target action dates in 2026[347]. - The company received an upfront payment and is eligible for milestone payments and royalties on net sales of MNKD-1501, a second investigational molecule being developed in collaboration with United Therapeutics[349]. - The company conducted a Phase 1 clinical study of MNKD-201, which met its primary objective, and is currently conducting a Phase 1b study with top-line data expected in early 2H 2026[352]. - The company has established regional partnerships for the commercialization of its products outside the U.S., including an initial shipment of Afrezza to its partner in India, Cipla, in December 2025[348]. - The company acquired scPharma in October 2025, which developed Furoscix, the first FDA-approved subcutaneous loop diuretic for home use[350]. - The company is exploring the feasibility of formulating bumetanide as a dry-powder for oral inhalation, which is a more potent loop diuretic than furosemide[353]. - The company is actively monitoring risks related to manufacturing capabilities and potential changes in U.S. tariff policy that may affect raw material costs[354].